Introduction
============

Spinal cord injury (SCI) is a severe complication of the spine, leading to severe dysfunction below injured segment. SCI puts pressure on a country's health services whiles also burdening an affected individual's family and society. The International Spinal Cord Society Prevention Committee estimates global-incident rate to be 23 traumatic SCI cases per million ([@B47]). SCI is categorized into primary injury and secondary injury phases on the basis of its pathophysiology. Although primary injury is transient and can be caused by a mechanical force, it, nevertheless, creates a basic environment for succeeding pathological events. Secondary injury includes a chain of pathological events such as apoptosis, inflammatory response, and excitotoxicity ([@B73]). SCI can result in different spinal cord dysfunctions and induce complications in other organs such as the lung ([@B34]). As primary injury phase is transient, SCI treatment could focus on the secondary injury phase. With that said, there is presently no effective SCI treatment.

Several researches have demonstrated NF-κB to be a crucial mediator of cellular responses to numerous physiological stimuli. NF-κB signaling pathway has been shown to participate in mediating SCI pathophysiology, subsequently playing a pivotal role in repairing SCI. Inhibition of NF-κB by different drugs potentially alleviates SCI ([@B95], [@B93]; [@B60]). In view of this, inhibition of NF-κB could be a potential target for SCI improvement.

Resveratrol, a potent inhibitor of NF-κB, is non-toxic, inexpensive and has multiple pharmacological effects on SCI recovery ([@B96]). Resveratrol can modulate cellular growth, autophagy, and immune response by regulating some signaling pathways such as NF-kB, SIRT1, PI3K/Akt/mTOR, ROS/Nrf2/NAF-1, and MAPK pathways ([@B42]; [@B14]; [@B17]). This review aims to systematically analyze resveratrol's role in regulating NF-κB signaling pathway in the wake of SCI.

Pathophysiology of Sci
======================

Secondary injury phase involves a number of pathophysiological processes including vascular changes such as hemorrhage and breakdown of BSCB, inflammation, peroxidation of lipid membranes and neural cell apoptosis ([@B73]). Spinal cord edema after SCI induces BSCB opening, leading to release of deleterious substances from blood cells such as neutrophils and macrophages, ultimately resulting in cell death as well as permanent neurological disability ([@B48]). Inflammatory response is important in SCI development. Inflammation follows immune response, which protects against pathogen. However, excessive inflammation causes damage to body. Major participatory cells of inflammation in SCI include macrophages, endothelial cells, microglia and astrocytes. Classical macrophage (M1) promotes inflammation while alternative macrophage (M2) has a contrasting effect on inflammation. M1 phenotype, activated by Th1 cytokines, LPS-induced signal transducer and activator of transcription 1 signaling, induces pro-inflammatory cytokines (TNF-α, IL-1, IL-1β, IL-6, and IL-12) and nitric oxide, leading to SCI disruption. On the contrary, Th2-induced M2 phenotype promotes anti-inflammatory cytokines (IL-10, TGF-β), contributing to attenuation of damage in injured spinal cord ([@B57]). [@B41] reported myelin lipid debris, a hallmark of SCI, to be a potent macrophage stimulus. Additionally, it was the target of complement-mediated clearance and inflammation, which was possibly cleared through macrophage surface receptors. Downstream results are determined by myelin-driven events that make macrophages a double-edged sword. Although macrophages are able to promote axonal growth, stem cell differentiation and tissue revascularization to facilitate repair of injured spinal cord, they (i.e., macrophages) can also contribute to SCI pathology through several mechanisms such as release of pro-inflammatory cytokine ([@B41]). Inflammation is thought to have an antithetical effect on neuroprotection in SCI. Changing process of different inflammatory factors and cells is different on temporal sequence after CNS trauma ([@B24]). At some point during inflammatory response from destructive to constructive, drugs could improve the pathological process by interfering with inflammatory cells and their released products. In an experimental study of NSC transplantation in SCI, results evinced NSC transplantation to modulate inflammation and enhance neurological function following SCI by reducing M1 macrophages' inflammatory activity and infiltration of neutrophils ([@B18]).

Reactive oxygen species (ROS) and oxidative stress are important events that have been associated with SCI. Both neuronal and glia cells in injured spinal cord are sensitive to oxidative and electrophilic stress ([@B33]). Ketone metabolite, β-hydroxybutyrate, has been reported to have the capability of inhibiting class I HDACs so as to attenuate oxidative stress in SCI. Selected suppression of either HDAC1 or HDAC2 systematically mediates FOXO3a, NOX2 and NOX4 expressions ([@B40]). Regarding excitotoxicity, studies have reported glutamate receptors to mediate cell death, which was potentiated by TNF-α ([@B5]). All these disparate mechanisms could potentially interact with each other and culminate in axonal demyelination, glial scars and neuronal diminution.

Nf-κB Signaling Pathway Following Sci
=====================================

Nuclear factor kappa-light-chain-enhancer of activated B cells is comprised of NF-κB family, inhibitor of NF-κB (IκB) and IKK. NF-κB family, also called NF-κB/Rel family, includes NF-κB1 (p50), NF-κB2 (p52), p65 (RelA), c-Rel and RelB. IκB family consists of IκBα, IκBβ and IκB𝜀 ([@B1]; [@B30]). IKK is a large protein complex that modulates phosphorylation of κB inhibitor. In resting cells, inactive NF-κB has been associated with inhibitor proteins, IκBα, IκBβ, or IκB𝜀, masking its nuclear localization sequence and inhibiting its DNA-binding activity ([@B61]). In spinal cord, NF-κB transcription factors are expressed in glial cells and blood vessels, which functions mainly in mediating various mechanisms such as inflammation.

Exhibition of Inflammation
--------------------------

Inflammatory signs can be detected during acute phase of SCI as cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), interleukin-6 (IL-6) and interleukin receptors (IL-4R and IL-2Ra) are upregulated from 0.5 to 6 h following injury. Four main inflammatory cells (neutrophils, monocytes, lymphocytes and microglias) are assembled and release inflammatory cytokines. These pro-inflammatory factors, at low concentration, could trigger inflammation in order to protect normal tissues in spinal cord. When these pro-inflammatory factors are overexpressed, they tend to activate transcription factors such as NF-κB that could cause cell death, subsequently altering role of pro-inflammatory factors from positive to negative ([@B4]). Following that, inflammation could create an environment that instigates other pathological events. Among transcription factors that are negative result of inflammation, NF-κB is of great importance. Once stimulated by either inflammatory intercellular signals or other signals like oxidative stresses such as free radicals, metabolic stress, or genotoxic stress in SCI, NF-κB signaling pathway could be induced by "classical" and "alternative" pathways.

In the "classical" pathway, NF-κB is mediated by activation of a number of cell surface receptors, including TLRs, IL-1 receptor, and TNF receptor. TLRs, a type I transmembrane proteins with extracellular domains, has a close contact relationship with NF-κB. In one of TLR signaling pathway, MyD88-dependent pathway, TLR recruits toll-interleukin 1 receptor domain containing adaptor protein at the cell membrane, facilitating recruitment of MyD88, which in turn could trigger early-phase activation of NF-κB. In another TLR signaling pathway, namely TIR-domain-containing adapter-inducing interferon-β (TRIF)-dependent pathway, TLR4 forms a signaling complex with TRIF-related adaptor molecule and TRIF, potentially culminating in late-phase activation of NF-κB, interferon regulatory factor 3 activation and interferon-β transcription ([@B37]). IKK phosphorylates two N-terminal serines of IκBα and IκBβ leading to poly ubiquitination of IκBs. Then, IκBs degrade via 26S proteasome that possibly activates NF-κB ([@B91]; [@B61]). Eventually, NF-κB liberated from IκBs enters the nucleus to activate target gene expression, leading to possible differential effect on gene expression.

The "alternative" pathway triggered by activation of TNF-receptor initiates NIK to stimulate IKKα-induced phosphorylation and proteolytic processing of cytoplasmic NF-κB2 precursor. Activated NF-κB2, RelB and NIK form a complex to enter the nucleus, potentially activating gene expression. This pathway is mainly involved in immune response ([@B11]). Various pro-inflammatory molecules like TNF-α, IL-1, IL-6 and inducible NOS are mediated by nucleus NF-κB complex, possibly engendering inflammation in spinal cord.

Hydroxysafflor yellow A (HSYA) has anti-inflammatory and anti-oxidative effects on neuronal protection ([@B95]). [@B64] study evidenced effects of HSYA inhibiting NF-κB activation and curtailing TNF-α and IL-6 in spinal cord after HSYA treatment, which confirms the vital role of NF-κB in exhibition of inflammation in SCI. Also, expression of miR-372 is stimulated in cultured human NSCs by IL-1β possibly binding with NF-κB at its promoter region. Thus, miR-372 could potentially be involved in inflammatory signaling mediated by NF-κB ([@B99]). Again, TWEAK, Fn14 and NF-κB had a synchronous alteration in a conducted study. Down-regulation of TWEAK curtailed TNF-α and IL-1β expressions. This suggests stimulation of TWEAK-Fn14 pathway might promote NF-κB expression and possibly culminate in elevated expression level of inflammatory cytokines ([@B87]).

Free Radicals and Lipid Peroxidation
------------------------------------

Free radicals are mainly from endoplasmic reticulum and mitochondria. Reactions between free radicals and polyunsaturated fatty acid of plasma membrane peroxidates and disrupt normal phospholipid structure of cellular biomembrane system ([@B32]). NF-κB can be mediated by free radicals. NF-κB activation is induced by TNF-α, IL-1β, TLRs, or antigen receptor (TCR, BCR) ligation, which promotes expression of a number of genes ([@B27]). These genes, which include mitochondrial MnSOD, are involved in anti-oxidative stress response. MnSOD is an enzyme that inhibits TNF-α-induced ROS production and cell death ([@B35]). Inhibition of NF-κB sustains oxidative stress and stimulates either apoptosis or necrosis of cells. In contrast to ROS, induced NOS from different sources like endothelial cells and neurons trigger S-nitrosylation of JNK1 and IKKb protein kinases to impede autophagic flux in mammalian cells. S-nitrosylation of JNK1 stabilizes Beclin 1/B-cell lymphoma-2 (Bcl-2) complexes by reducing phosphorylation of Bcl-2, which can potentially block early steps of formatting autophagic membranes. S-nitrosylation of IKKb has same effect as JNK1 on Adenosine 5′-monophosphate (AMP)-activated protein kinase phosphorylation in suppressing autophagy initiation ([@B36]). NF-κB, c-Fos and c-Jun expressions, as activators of oxidative response markers, suggest possible augmented production of ROS is likely to give rise to cascades of oxidative destruction. Also, lipid peroxidation and nucleic acid oxidation are elevated in injured spinal cord and motor neurons. Consequently, increased degeneration of ROS could contribute to motor neuronal death in spinal cord, which is an early causal event in the wake of SCI ([@B88]).

Apoptosis and Demyelination of Axons
------------------------------------

Though neuronal damage in SCI occurs predominantly through necrosis, apoptosis cannot be ignored. Intracellular hypercalcemia induced by loss of ionic homeostasis after SCI activates calcium-dependent proteases and results in mitochondria dysfunction, eventually leading to apoptotic cell death ([@B72]). Signaling pathways such as Fas/FasL have been evidenced to mediate apoptosis. NF-κB has been reported to be involved in apoptosis. A recent study evinced that during early phase of SCI, TWEAK might assemble pro-inflammatory factors to instigate cell apoptosis through its effect on NF-κB expression ([@B87]). RIPK1 functions as a node which drives cell survival and inflammation mediated by NF-κB, caspase-8-dependent apoptotic and RIPK3/MLKL-dependent necroptotic cell death ([@B75]). Interplay between IKK/NF-κB and RIPK1 signaling is an important determinant of tissue homeostasis and inflammation. In the intestine and liver, NEMO regulates RIPK1 kinase activity-mediated apoptosis through NF-κB-dependent and independent functions, which are crucial for inhibiting chronic tissue injury and inflammation ([@B39]). A new function of TAK1 was reported to regulate checkpoint of early NF-κB-independent cell death in TNFR1 apoptotic pathway. Ub chains conjugated with RIPK1 or other TNFR1 complex I functions as scaffolds in the recruitment and activation of TAK1-binding protein 2/3--TAK1 complex and inhibition of IKK complex (NEMO-IKKa-IKKb), potentially triggering off mitogen-activated protein kinases and classical NF-κB signaling pathways that collectively promotes gene transcription, preventing cell death and sustaining inflammation. Thus, a pro-survival TNFR1 ligation will switch to a pro-apoptotic one when NF-κB response is potentially inhibited ([@B23]). Besides, ROS is related to apoptosis. A previous study reported ROS generation to be required for TNF-mediated necroptosis ([@B80]). ROS scavenging has the potentiality of inhibiting caspase activation and assembly of complex IIb on TNF stimulation ([@B23]). Microglia-derived TNF-α was found to induce Puma expression, a member of BH3-only family in NPCs via an NF-κB-dependent mechanism. More specifically, NF-κB was activated in NPCs cultivated with conditioned media from activated microglia. Also, NF-κB inhibitor, BAY-117082, blocks Puma induction, and NPC apoptosis ([@B28]). There are reports stating taxifolin might possibly reduce neuronal apoptosis induced by cholesterol oxidation product through suppression of cell death mediated by Akt and NF-κB activation ([@B38]). In the only contrasting study, neuroprotective effect of neuronal IKK-2 in autoimmune demyelination was reported ([@B25]). In rats, loss of oligodendrocytes could possibly lead to axonal demyelination and peaks at about 24 h following injury. Persistent demyelination is related to atrophy and potential death occurring in related cell bodies ([@B69]). When demyelination happens in SCI, microglia phagocytizes myelin debris ([@B9]). Degenerated myelin containing inhibitory molecules like NogoA and Oligodendrocyte-myelin glycoprotein activates FAK/PI3K/Akt/NF-κB pathway in macrophages and promotes expression of inflammatory mediators ([@B74]). Activated astrocytes and microglia potentially enhances NF-κB activation. However, there are no reports of NF-κB activation in oligodendrocytes. During remyelination, NF-κB in recruited oligodendrocyte progenitor cells is activated. These progenitor cells, which engage demyelinated axons, are differentiated into remyelinating oligodendrocytes ([@B9]). A study found E6020 to induce TLR4-dependent cytokine expression such as TNFα, IL1β, IL-6 and NF-κB signaling *in vitro*. Injection of E6020 with lysolecithin into rat spinal cord white matter increased axonal sparing, accelerated myelin debris clearance, enhanced Schwann cell infiltration into demyelinated lesions and increased number of remyelinated axons ([@B20]). Taking all these studies into consideration, NF-κB signaling pathway is predominately involved in various pathophysiological mechanisms of SCI, especially with regards to inflammation.

Resveratrol Inhibits Nf-κB Signaling Pathway
============================================

Resveratrol (*trans*-3,5,4-trihydroxystilbene), a small natural polyphenol found in red wine, grapes, peanuts and other different kinds of plant sources is widely studied and used in therapies of different diseases. Resveratrol, used in Indian herbal, traditional Chinese, and Japanese medicine for human health, can be traced back 2000 years ago, with a prime example of a well-known Indian herbal preparation being "darakchasava." Resveratrol is a naturally polyphenolic phytoalexin first identified from *Veratrum grandiflorum* in 1939 ([@B76]) and later detected in dried roots of *Polygonum cuspidatum*, in the leaf epidermis and skin of grape berries. Resveratrol was initially applied to treat injuries ([@B46]). Cardiovascular effect of red wine was called "the French paradox," with resveratrol attracting widespread attention in the early 1990s ([@B67]). [@B85] initially reported resveratrol to extend lifespan in yeast and in worms. Since then, numerous beneficial effects of resveratrol have been reported in different pathological conditions, experimental models and clinical studies. A growing body of evidence shows resveratrol might play potential therapeutic roles in cardiovascular disease, cancer, ischemic injury, sarcopenia, diabetes, obesity, respiratory diseases, osteoarthritis and neurodegeneration (**Table [1](#T1){ref-type="table"}**). It has various pharmacological effects such as anti-oxidative, anti-inflammation, cardiovascular protection, anti-diabetic, restoration of immune system function ([@B45]), anti-apoptosis ([@B31]), anti-nociception ([@B63]), anti-depression ([@B26]), anti-cancer activities ([@B19]; [@B43]), neuronal protection ([@B59]) and regulation of metabolism ([@B55]). Biological activity of resveratrol can possibly be achieved by mediating NF-κB ([@B79]), heme oxygenase-1 (HO-1) ([@B70]), mitogen-activated protein kinase (MAPK) ([@B56]), endothelial nitric oxide synthase (eNOS) ([@B86]), nuclear factor E2-related factor-2 (Nfr2) ([@B17]), estrogen receptor (ER) ([@B71]) and HDAC SIRT1 ([@B14]). Based on enumerated effects, there are reports positing resveratrol could potentially be employed in the treatment of medical conditions such as Alzheimer's disease ([@B58]), diabetes, cardiovascular diseases as well prostate and breast cancers ([@B19]; [@B43]; [@B92]). Resveratrol functions via several signaling pathways, one being NF-κB. Accumulating studies indicate inhibition of NF-κB signaling pathway by resveratrol potentially plays a significant role in various pathological processes (**Figure [1](#F1){ref-type="fig"}**).

###### 

Summary of beneficial effects of Resveratrol (RES).

  Diseases                 Species         Dose                 Results                                                                                                                         Reference
  ------------------------ --------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------- -----------
  Brain injury             Rat and mouse   60 or 90 mg/kg       RES has an efficient neuroprotection against subarachnoid hemorrhage                                                            [@B94]
  Cardiovascular disease   Rat             15 mg/kg             RES improves left ventricular function and decreases myocardial hypertrophy, fibrosis, and severity of heart failure.           [@B68]
  Neurodegeneration        Mouse           10 mg/kg             RES significantly attenuates acute neurological deficits, neurodegeneration and cerebral edema after intracerebral hemorrhage   [@B10]
  Sarcopenia               Rat             125 mg/kg            RES reduces apoptotic signaling in muscles of old animals                                                                       [@B6]
  Acute pancreatitis       Rat             10--50 mg/kg         RES attenuates pancreatic oxidative damage by down-regulating NF-κB and PI3K signaling pathways                                 [@B79]
  Obesity                  Mouse           15 mg/kg             RES increases Cidea mRNA level and UCP1 protein expression                                                                      [@B3]
  Diabetes                 Mouse           40 mg/kg                                                                                                                                             
                                                                                                                                                                                                [@B97]
                                                                RES attenuates testicular apoptosis in type 1 diabetic mice                                                                     
  Respiratory diseases     Mouse           50 mg/kg, 40 μg/ml   RES relieves LPS-induced inhibition on SIRT1 expression and restrains activation effects of LPS on MAPKs and NF-κB activation   [@B56]
  Kidney injury            Rat             0.23 μg/kg           RES inhibits inflammatory responses and improves renal function after renal Ischemia-reperfusion injury                         [@B50]
  Colorectal cancer        Human           5 μM                 RES induces apoptosis, suppresses NF-κB activation                                                                              [@B13]
  Thyroid cancer           Rat             100 μM               RES inhibits NF-κB/p65 signaling, IL-6 and COX-2 expressions                                                                    [@B98]
  Breast cancer            Human           0--100 μM            RES inhibits breast cancer cellular proliferation                                                                               [@B65]
  Pancreatic cancer        Human           50 μM                RES promotes pancreatic cancer apoptosis through ROS/Nrf2/NAF-1 pathway                                                         [@B17]
  ovarian cancer           Human           10, 20, or 30 μM     RES reduces cell growth and metabolism of SKOV-3 aggregates                                                                     [@B77]
  Liver cancer             Human           100 μM               RES inhibits PI3K/AKT pathway by SIRT1 activation                                                                               [@B14]
  Gastric cancer           Human           100 μM               RES inhibits growth of MGC-803 cells by inhibiting Wnt signaling pathway                                                        [@B22]
  Prostate cancer          Mouse           625 mg/kg                                                                                                                                            
                                                                                                                                                                                                [@B29]
                                                                RES suppresses prostate cancer progression                                                                                      
  Osteoarthritis           Rat             50 mg/kg             RES reduces inflammatory responses by inhibiting NF-κB expression                                                               [@B84]

![Negative effects of resveratrol on NF-κB via several pathways in SCI. In TNFR1 apoptotic pathway, Ub chains conjugated with RIPK1 function as scaffolds in the recruitment and activation of TAK1-binding protein 2/3--TAK1 complex and inhibition of IKK complex (NEMO-IKKa-IKKb), subsequently triggering off the classical NF-κB signaling pathways that collectively promote transcription of genes, which prevents cell death and sustains inflammation. In MyD88-dependent pathway, TLR recruits toll-interleukin 1 receptor domain containing adaptor protein at the cell membrane, subsequently facilitating recruitment of MyD88, which in turn triggers early-phase activation of NF-κB. Recruitment of TRAM and TRIF leads to late-phase activation of NF-κB. IKK phosphorylates IκBα and IκBβ leading to poly ubiquitination of IκBs. Degradation of IκBs results in activation of NF-κB. Besides, degenerated myelin activates FAK/PI3K/Akt/NF-κB pathway in macrophages and promotes expression of inflammatory mediators. Stimulation of TWEAK-Fn14 pathway also promotes NF-κB expression. On the contrary, SIRT1 inhibits NF-κB activation. Eventually, NF-κB enters the nucleus to activate target gene expression. Resveratrol potentially enhances SIRT1 and AMPK expressions. AMPK activation increases NAD+/NADH ratio and triggers its downstream whereas SIRT1 acts as an anti-inflammatory NAD+-dependent deacetylating enzyme via direct deacetylation of subunit of NF-κB such as p65, SIRT1 directly interacts with RelA/p65. Also, resveratrol suppresses IKK activity.](fnins-12-00690-g001){#F1}

Reports evidence resveratrol to suppress various cytokines such as TGFβ, MMP, COX-2, TNF-α, IL-1β, IL-6 and intercellular cell adhesion molecule-1 (ICAM-1). All these demonstrate the linkage between resveratrol and NF-κB owing to expression of these cytokines being mediated by NF-κB signaling pathway. In liver diseases, prevention of fibrosis by resveratrol is concomitant with preventing translocation of NF-κB and down-regulating profibrotic cytokine TGFβ ([@B15]). In a rat model of early polymicrobial sepsis-induced acute kidney injury, resveratrol significantly improved tubular epithelial cell injury and renal function, subsequently enhancing rat survival rate. This was concomitant with substantial decrement of TNF-α, IL-1β and IL-6 expressions in serum content and renal mRNA ([@B83]). Resveratrol reduces ICAM-1 expression in attenuation of endothelial inflammation, which is partly mediated through miR-221/222/AMPK/p38/NF-κB pathway ([@B52]). In human fibroblast-like synoviocytes, resveratrol was reported to inhibit COX-2/PGE expression so as to suppress particulate matter-induced inflammatory signaling pathways ([@B78]). Moreover, resveratrol acts on two critical transcription factors to downregulate COX-2 expression: p50/p65 under the control of signaling cascade IKKBα/IκBα and activator protein-1 complex of MAPK/ERK/p38/JNK ([@B7]; [@B44]; [@B21]). In ovarian cancer cell aggregates, resveratrol and acetyl-resveratrol potentially inhibits cell growth, which is correlated with decreased secretion of vascular endothelial growth factor and attenuation of NF-κB ([@B77]). As an NF-κB signal transduction inhibitor, resveratrol inhibits MMP-9 and COX-2 so as to prevent disruption of blood brain barrier during neuroinflammation in carcinogen-induced brain endothelial cells ([@B2]).

Inhibition of p65 subunit translocation by resveratrol to the nucleus is a mechanism that was deduced from an experimental hepatocarcinogenesis model ([@B8]). Resveratrol decreases IκB phosphorylation as well as phosphorylation, acetylation and translocation of NF-κB p65 induced by TNF-α ([@B52]). Reduction of IκB phosphorylation, p65 protein levels in nucleus and NF-κB transcriptional activity by resveratrol is involved in resveratrol-induced apoptosis ([@B49]). Resveratrol can potentially regulate levels of NF-κB-mediated miRNAs. Resveratrol inhibits miR-21 expression to suppress NF-κB activity ([@B49]). Resveratrol was reported to downregulate miR-21 expression and other comiRs including miR-30a-5p, miR-19 as well as their targeted or related components ([@B81]). Interestingly, in U251 cells, over-expression of miR-21 reversed resveratrol on NF-κB activity and apoptosis ([@B49]).

Also, resveratrol requires the enzyme, SIRT1, so as to inhibit upregulation of NF-κB-regulated gene products in promoting chondrogenic differentiation of mesenchymal stem cells ([@B12]).

Resveratrol's Stimulation of Sci Amelioration Is Correlated to Nf-κB Signaling Pathway Inhibition
=================================================================================================

Though resveratrol has multiple beneficial health effects such as anti-inflammation and anti-apoptosis, some of these effects on SCI protection still remain unclear. Resveratrol significantly exerts effect on preserving structure and morphology of damaged tissues, protecting neurons from traumatic injury-induced apoptosis and promoting locomotive activity of hindlimb motor neurons in rats following SCI, which is possibly related to its pleiotropic effects including anti-oxidation, anti-inflammation and anti-apoptosis. Resveratrol improves recovery of injured tissues in spinal cord via mediating participatory cytokines. Regarding anti-oxidation, resveratrol can reversely increase superoxide dismutase and decrease malondialdehyde to inhibit oxidation in SCI. Thus, resveratrol can potentially accelerate scavenging and protect cellular structure from damage to inhibit overproduction of free radicals. Concerning anti-inflammation, resveratrol can potentially curtail injury-induced myeloperoxidase and other inflammatory factors such as IL-10 and TNF-α and relieve neutrophil infiltration to inhibit inflammation cascade. On the subject of anti-apoptosis, resveratrol could elevate expression of Bcl-2, the anti-apoptotic substrate while inhibiting Bax and caspase-3, which attenuates triggering of apoptosis and reducing neuronal death ([@B51]).

Also, resveratrol could mediate SIRT1-AMPK signaling pathway to regulate autophagy and apoptosis that possibly plays a neuroprotective role in SCI. Resveratrol was found to enhance SIRT1 and AMPK expressions. Apoptotic expression is significantly suppressed by resveratrol on protein and mRNA level, which could possibly be related to the up-regulation of SIRT1/AMPK signaling pathway in the wake of SCI. Both SIRT1 and AMPK are crucial substrates in mediating autophagy ([@B96]). AMPK activation increases NAD+/NADH ratio and triggers its downstream whereas SIRT1 acts as an anti-inflammatory NAD+-dependent deacetylating enzyme via direct deacetylation of subunit of NF-κB such as p65 ([@B90]; [@B89]). SIRT1 directly interacts with RelA/p65 via deacetylation of RelA/p65 on lysine 310, a site crucial for NF-κB transcriptional activity, to inhibit NF-κB transcription. Employment of resveratrol potentiates SIRT1 protein on cIAP-2 gene, an effect that possibly correlates with liberating cIAP-2 gene from regulation of NF-κB and sensitizing cells to TNFα-induced apoptosis ([@B90]). Besides, SIRT1 can potentially inversely activate AMPK or induce phosphorylation of peroxisome proliferators activated receptor-γ coactivator-1α, thereby inhibiting RelA/p65-mediated NF-κB signaling. AMPK has been evinced to be a negative regulator of NF-κB signaling and is involved in inflammatory response in macrophages ([@B66]; [@B62]). These negative effects by SIRT1-AMPK signaling pathway on NF-κB activity leads to enhanced IL-12 production and anti-inflammation ([@B54]).

There is the possibility of resveratrol inhibiting NF-κB activity via SIRT1-AMPK signaling pathway to exert its beneficial effects on improving SCI. Hence, SIRT1-AMPK signaling pathway can be a possible bridge connecting autophagy and inflammation. Studies have indicated polydatin, a glucoside of resveratrol, to possess potent antioxidative effects. It has the potentiality of partly solving the problem of poor viability of transplanted bone marrow stem cells (BMSCs), which limits therapeutic efficacy. Thus, polydatin with BMSCs could possibly improve therapeutic effect of SCI ([@B16]). Resveratrol attenuates SCI-induced inflammatory damage in rats' lungs, which was accompanied by curtailment of pro-inflammatory factors, up-regulation of SIRT1 and anti-inflammatory cytokines as well as suppression of NF-κB activity ([@B53]). Resveratrol was also demonstrated to exert some effect on enervated sub-lesional bone loss that is associated with repressed oxidative stress, curtailed inflammation, depressed peroxisome proliferators-activated receptor γ signaling and restored Wnt/β-catenin and insulin-like growth factors-1 signaling in SCI rats ([@B82]).

Conclusion
==========

Nuclear factor kappa-light-chain-enhancer of activated B cells signaling pathway plays a crucial role in exhibition of inflammation, promotion of damage caused by free radicals and lipid peroxidation as well as facilitation of apoptosis and axonal demyelination in SCI. Resveratrol has been studied in the treatment of various diseases in different organs via NF-κB signaling pathway. Beneficial effect of resveratrol in SCI is explicated as evidenced previously. Thus, we hypothesize resveratrol to potentially improve SCI by inhibiting NF-κB signaling pathway. With that said, more direct researches are needed to explore interior mechanisms between resveratrol and NF-κB signaling pathway following SCI, which in turn could support promising value of resveratrol in SCI therapy. Finally, appropriate and precise phase at which resveratrol can be employed needs to be elucidated.
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